Review of clinical experience with amdinocillin monotherapy and comparative studies.
Activity against gram-negative bacilli and frequent synergism with other beta-lactam antibiotics were demonstrated by amdinocillin in urinary tract infections, urosepsis, and in a variety of other infections. In a prospective study, 299 patients were assigned at random to receive amdinocillin or another antibiotic considered standard treatment for the infection. The majority of infections were of the urinary tract, and 58 of 59 patients treated with amdinocillin responded clinically, with cures in 49. Of the 52 patients treated with tobramycin or other comparative agents, 49 responded, and 42 were cured. Escherichia coli and other Enterobacteriaceae were the usual pathogens. Immediately after treatment, 90 percent of urine samples were negative in both treatment groups. At four to six weeks follow-up, relapse or reinfection rates were about 20 percent in either group. Miscellaneous infections were treated with either amdinocillin or a comparative agent. Eleven of 15 infections responded favorably to amdinocillin, and seven were cured. Adverse effects were usually mild and characteristic of the penicillins.